Inogen’s (INGN) Hold Rating Reiterated at Needham & Company LLC

Needham & Company LLC restated their hold rating on shares of Inogen (NASDAQ:INGN) in a report released on Wednesday,Benzinga reports.

Separately, StockNews.com lowered shares of Inogen from a “buy” rating to a “hold” rating in a research note on Wednesday, February 26th.

Inogen Stock Down 2.8 %

NASDAQ:INGN traded down $0.20 during trading hours on Wednesday, reaching $6.84. 155,499 shares of the stock were exchanged, compared to its average volume of 241,359. Inogen has a twelve month low of $6.40 and a twelve month high of $13.33. The business has a 50-day moving average of $8.51 and a two-hundred day moving average of $9.27. The company has a market capitalization of $183.91 million, a price-to-earnings ratio of -3.05 and a beta of 1.48.

Institutional Trading of Inogen

Several hedge funds have recently modified their holdings of INGN. AlphaQuest LLC acquired a new stake in Inogen in the 4th quarter valued at about $43,000. Meeder Asset Management Inc. acquired a new stake in Inogen in the fourth quarter valued at approximately $56,000. Integrated Quantitative Investments LLC purchased a new position in Inogen in the fourth quarter worth approximately $92,000. Ieq Capital LLC acquired a new position in Inogen during the 4th quarter worth approximately $94,000. Finally, Intech Investment Management LLC purchased a new stake in shares of Inogen in the 4th quarter valued at approximately $94,000. 89.94% of the stock is currently owned by institutional investors and hedge funds.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.